MERCK

A  Six  Month  Phase  II/III,  Randomized,  Double- Blind, PlaceboControlled Clinical  Trial  to  Evaluate  the Safety,Tolerability,  and  Efficacy  of  Telcagepant (MK-0974)  for  Prevention  of Menstrually Related Migraine  in  Female Patients with Episodic Migraine.